drug · small molecule
olverembatinib
Phase 3updated 3mo agoby $AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
targets
Bcr/Abl fusion protein
all catalysts(0)
nothing on the calendar yet
Trials studying olverembatinib
- EP1Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
- phase1A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
- phase2Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- phase2Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
- phase1Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
- phase2Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
- phase3Study of Olverembatinib (HQP1351) in Patients With CP-CML
- phase3A Study of Olverembatinib in SDH-deficient GIST.
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that